Table 3.
Prediction performance of the signature in the validation set by the fixed cut-off point.
| Distinction | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) | Disease prevalence (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|
| AR vs STA (n = 179) | 0.84 (0.778 - 0.899) | 70.18 (56.60% - 81.57%) | 80.33 (72.16% - 86.97%) | 62.5 (52.85% - 71.25%) | 85.22 (79.31% – 89.66%) | 77 (70.24% - 83.03%) | 31.84 (25.09% - 39.21%) | <0.0001 |
| AR vs OGIs (n=142) | 0.703 (0.617 - 0.789) | 70.18 (95% CI: 56.60 - 81.57) | 60.00 (95% CI: 48.80 - 70.48) | 54.05 (95% CI: 46.31 - 61.61) | 75.00 (95% CI: 66.02 - 82.24) | 64 (95% CI: 55.61 - 71.96) | 40.14 (32.01 to 48.69) | <0.0001 |
| AR vs STA + OGIs (n = 264) | 0.783* (0.721 - 0.845) | 70.18 (56.60% - 81.57%) | 71.98 (65.33% - 77.98%) | 40.82 (34.35% - 47.62%) | 89.76 (85.37% - 92.94%) | 72 (65.74% - 76.95%) | 21.59 (16.78% - 27.05%) | <0.0001 |
*AUC was calculated based on AR predicted probability of the signature for patients including AR (n=57), STA (n=122), OGIs (n=85), and no-AR (STA and OGIs, n=207) in QC-passed samples. PPV, positive predictive value; NPV, negative predictive value.